FDA Pauses PepGen’s DMD Drug Trial In The US: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2025

  • curprev 09:3009:30, 16 August 2025 MargheritaEvers talk contribs 5,288 bytes +5,288 Created page with "<br>The therapy was being evaluated in ascending doses in the 25-week, Read more multinational, double-blind, placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 t..."
Retrieved from "http://wiki.subadvocates.org/index.php/FDA_Pauses_PepGen’s_DMD_Drug_Trial_In_The_US"